<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765228</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1912212-12</org_study_id>
    <nct_id>NCT04765228</nct_id>
  </id_info>
  <brief_title>Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma</brief_title>
  <official_title>A Prospective One-arm Study of Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective one-arm study of pegylated liposomal doxorubicin combined with anlotinib for&#xD;
      neoadjuvant treatment of locally advanced soft tissue sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor angiogenesis is very important in the occurrence and development of soft tissue&#xD;
      sarcoma. The current clinical studies of molecularly targeted drugs are focused on the&#xD;
      advanced treatment stage of soft tissue sarcoma. Anti-angiogenic drugs are not yet available&#xD;
      in the neoadjuvant treatment stage of soft tissue sarcoma. Strong evidence. Therefore, this&#xD;
      study aimed to evaluate the safety and effectiveness of pegylated doxorubicin liposomes&#xD;
      combined with the anti-angiogenic drug Anlotinib for neoadjuvant treatment of patients with&#xD;
      soft tissue sarcoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 21 days)</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR rate</measure>
    <time_frame>One year after the first intravenous drip</time_frame>
    <description>Pathological complete response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>6 weeks after the first intravenous drip</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>After the first intravenous drip,an average of 3 year through study completion</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Pegylated liposomal doxorubicin + Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles</description>
    <arm_group_label>Pegylated liposomal doxorubicin + Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib</description>
    <arm_group_label>Pegylated liposomal doxorubicin + Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with soft tissue sarcoma confirmed by histopathology;&#xD;
&#xD;
          2. Patients with soft tissue sarcoma judged to be stage IIB/III according to the AJCC&#xD;
             staging of soft tissue sarcoma, or tumors that are closely related to important blood&#xD;
             vessels and important nerves suggested by imaging data;&#xD;
&#xD;
          3. No distant transfer&#xD;
&#xD;
          4. According to the preliminary judgment of the research, patients who can improve the&#xD;
             effect of surgery by neoadjuvant treatment;&#xD;
&#xD;
          5. Male or female, aged ≥14 years old and ≤75 years old;&#xD;
&#xD;
          6. ECOG score ≤ 2;&#xD;
&#xD;
          7. The expected survival period is ≥3 months;&#xD;
&#xD;
          8. Adequate hematopoietic function: absolute neutrophil count (ANC) ≥ 1.5×109/L and&#xD;
             platelet count ≥ 80×109/L and hemoglobin ≥ 9 g/dL;&#xD;
&#xD;
          9. Sufficient liver function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT&#xD;
             ≤ 1.5 times the upper limit of normal (ULN); alkaline phosphatase ≤ 5 times the upper&#xD;
             limit of normal (ULN);&#xD;
&#xD;
         10. Adequate renal function: serum creatinine ≤ upper limit of normal (ULN) or calculated&#xD;
             creatinine clearance ≥ 60 mL/min;&#xD;
&#xD;
         11. Visceral function: LVEF≥50%, the New York Society of Visceral Disease Association&#xD;
             (NYHA) has a functional classification of I and II, and there is no unhealed wound on&#xD;
             the body;&#xD;
&#xD;
         12. Sign the informed consent form.&#xD;
&#xD;
         13. Women should agree to use contraceptive measures (such as intrauterine device (IUD),&#xD;
             contraceptives or condoms) during the study period and within 6 months after the end&#xD;
             of the study; serum or urine pregnancy within 7 days before study entry The test is&#xD;
             negative and must be a non-lactating patient; men should agree to patients who must&#xD;
             use contraception during the study period and within 6 months after the end of the&#xD;
             study period.&#xD;
&#xD;
         14. The patient voluntarily joined the study, signed an informed consent form, had good&#xD;
             compliance, and was able to be followed up by the trial staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ewing's sarcoma, embryonic rhabdomyosarcoma, acinar rhabdomyosarcoma&#xD;
&#xD;
          2. Pregnant or breastfeeding women, or women who are fertile but have not taken&#xD;
             contraceptive measures&#xD;
&#xD;
          3. Existing severe acute infection that has not been controlled; or having purulent or&#xD;
             chronic infection, and the wound is protracted&#xD;
&#xD;
          4. Active hepatitis B or C&#xD;
&#xD;
          5. Have a history of other tumors within 5 years before treatment, except for cured&#xD;
             cervical carcinoma in situ or skin basal cell carcinoma&#xD;
&#xD;
          6. Those who have participated in other drug clinical trials within 4 weeks&#xD;
&#xD;
          7. Patients with pre-existing severe heart disease, including: congestive heart failure,&#xD;
             uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe&#xD;
             heart valve disease and refractory hypertension, ventricular tachycardia, ventricular,&#xD;
             Patients with atrial fibrillation, second-degree type II or third-degree&#xD;
             atrioventricular block, myocardial infarction within 1 year, congestive heart failure,&#xD;
             symptomatic coronary heart disease requiring medication&#xD;
&#xD;
          8. People with uncontrollable neurological or mental diseases or mental disorders, poor&#xD;
             compliance, unable to cooperate and describe the treatment response; primary brain&#xD;
             tumors or central nerve metastases have not been controlled, and have obvious&#xD;
             intracranial hypertension or neuropsychiatry Symptoms&#xD;
&#xD;
          9. Past severe chronic skin diseases&#xD;
&#xD;
         10. People with bleeding tendency, evidence of hereditary bleeding constitution or&#xD;
             coagulopathy&#xD;
&#xD;
         11. Have a clear history of allergy to chemotherapy drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Chen, M.D.</last_name>
    <phone>18017317571</phone>
    <email>chenyong@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen C Yong, M.D.</last_name>
      <phone>13917530417</phone>
      <email>chenyong@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yong Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Yong Chen</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

